Video

Dr. Garcia on Selecting Second-line Immunotherapy in Bladder Cancer

Author(s):

Jorge Garcia, MD

In Partnership With:

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses selecting a second-line and beyond immunotherapy treatment for patients with bladder cancer.

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses selecting a second-line and beyond immunotherapy treatment for patients with bladder cancer.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Shubham Pant, MD, MBBS
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Related Content
Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs | Image Credit: © Katsyarina - stock.adobe.com
November 22nd 2024

NMPA Approves Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Versamune HPV in HPV16-Driven HNSCC ©stock.adobe.com
November 18th 2024

Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC

Aaron T. Gerds, MD, MS, assistant professor, Department of Medicine, School of Medicine, member, Developmental Therapeutics Program, Case Comprehensive Cancer Center, physician,Department of Hematology and Medical Oncology, Cleveland Clinic; James K. McCloskey, MD, interim chief, Division of Leukemia, Hackensack John Theurer Cancer Center
October 14th 2024

Navigating Myelofibrosis: Updates for Community Hematologist Oncologists

Alex F. Herrera, MD
November 14th 2024

Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma

IMA203 in Melanoma
November 11th 2024

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors